Peptides DB
Research-centric peptide and protocol reference hub

Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

2545studies indexed1158with human data159registered trials2232carry a numeric findingLibrarian added 0 studies today
Showing 30 studiesSortNewest indexed ▾
A
grade
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Survodutide (BI 456906) · Nature medicine · 2026 · RCT · Phase 3Top journal
In adults with obesity and at-risk MASLD, survodutide treatment resulted in significant reductions in liver fat and body weight compared to placebo.
84.2% of survodutide-treated patients versus 24.3% of placebo-treated patients had ≥30% reduction in LFC, P<0.0001.
B
grade
Spatial non-uniformity of liver virtual non-contrast attenuation on dual-layer spectral CT: Impact of body habitus and peripheral right-lobe error.
Survodutide (BI 456906) · European journal of radiology open · 2026 · Observational · n=99
In larger patients, central liver measurements may be preferred over peripheral measurements when evaluating diffuse liver attenuation using dual-layer CT.
Median absolute whole-liver TNC-VNC differences were 4.4 HU in the portal venous phase.
A
grade
Comparison of Keverprazan-based versus esomeprazole-based dual therapy for initial treatment of Helicobacter pylori infection: a prospective, multicenter, randomized controlled trial.
Survodutide (BI 456906) · Annals of medicine · 2026 · RCT
Keverprazan-amoxicillin therapy is non-inferior to esomeprazole-amoxicillin therapy for H. pylori eradication, but the differences in efficacy are not statistically significant.
Eradication rate for KA group was 87.9% vs 80.3% for EA group in ITT analysis, p=0.092.
C
grade
Ethnopharmacological validation of Capparis spinosa L. in gastrointestinal and respiratory disorders: Evidence from in vitro, in vivo, and in silico models.
Survodutide (BI 456906) · Journal of ethnopharmacology · 2026 · Observational
C. spinosa shows potential for reducing diarrheal episodes and fluid accumulation in animal models, supporting its traditional use for gastrointestinal issues.
C. spinosa (50-200 mg/kg) significantly (p < 0.05) lessened diarrheal episodes.
Showing 25 of 30